• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Convalescent Plasma for Covid-19 - Making Sense of the Inconsistencies.

作者信息

Estcourt Lise, Callum Jeannie

机构信息

From the Department of Haematology and Transfusion Medicine, University of Oxford, and National Health Service Blood and Transplant - both in Oxford, United Kingdom (L.E.); and the Department of Pathology and Molecular Medicine, Queen's University, and Kingston Health Sciences Centre, Kingston, and the Department of Laboratory Medicine and Pathobiology, University of Toronto, and Sunnybrook Research Institute, Toronto - all in Ontario, Canada (J.C.).

出版信息

N Engl J Med. 2022 May 5;386(18):1753-1754. doi: 10.1056/NEJMe2204332.

DOI:10.1056/NEJMe2204332
PMID:35507487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9093717/
Abstract
摘要

相似文献

1
Convalescent Plasma for Covid-19 - Making Sense of the Inconsistencies.用于治疗新冠病毒肺炎的康复期血浆——解读其中的不一致之处
N Engl J Med. 2022 May 5;386(18):1753-1754. doi: 10.1056/NEJMe2204332.
2
Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy.抗击新冠疫情：恢复期血浆作为一种紧急治疗方法的疗效
Am J Emerg Med. 2021 Mar;41:244-246. doi: 10.1016/j.ajem.2020.05.101. Epub 2020 Jun 2.
3
Convalescent plasma for COVID-19 considerations.关于新冠病毒病恢复期血浆的考量
Transfus Apher Sci. 2021 Feb;60(1):102927. doi: 10.1016/j.transci.2020.102927. Epub 2020 Aug 27.
4
Late Treatment for COVID-19 With Convalescent Plasma.新冠康复者血浆对新冠肺炎的延迟治疗
Chest. 2022 Nov;162(5):e283-e284. doi: 10.1016/j.chest.2022.07.029.
5
Is convalescent plasma still useful as a covid treatment?康复期血浆作为一种新冠治疗手段是否仍然有效？
BMJ. 2023 Nov 8;383:2185. doi: 10.1136/bmj.p2185.
6
Convalescent Plasma for Outpatients with Covid-19.新冠康复者血浆用于新冠肺炎门诊患者
N Engl J Med. 2021 Dec 2;385(23):2206. doi: 10.1056/NEJMc2114591. Epub 2021 Oct 13.
7
[Is convalescent plasma an alternative treatment for Covid-19 patients?].[康复期血浆是新冠病毒肺炎患者的替代治疗方法吗？]
Salud Publica Mex. 2020 Nov-Dec;62(6):870-871. doi: 10.21149/11744.
8
The Fast and the Furious: Chasing a Clinical Niche for COVID-19 Convalescent Plasma.《速度与激情：为 COVID-19 恢复期血浆寻找临床定位》。
Ann Intern Med. 2022 Sep;175(9):1332-1334. doi: 10.7326/M22-2329. Epub 2022 Aug 16.
9
The Association Between Convalescent Plasma Treatment and Survival of Patients with COVID-19.恢复期血浆治疗与新型冠状病毒肺炎患者生存之间的关联
J Gen Intern Med. 2021 Aug;36(8):2528-2531. doi: 10.1007/s11606-021-06894-3. Epub 2021 May 13.
10
COVID-19 Convalescent Plasma and Concomitant Therapies in PassITON.COVID-19康复期血浆及PassITON中的联合疗法。
Chest. 2022 Nov;162(5):e284-e285. doi: 10.1016/j.chest.2022.07.028.

引用本文的文献

1
Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial.在因 COVID-19 肺炎住院的肾功能受损人群中使用瑞德西韦的疗效和安全性：一项随机临床试验。
Clin Infect Dis. 2024 Nov 22;79(5):1172-1181. doi: 10.1093/cid/ciae333.
2
Experiences in the use of multiple doses of convalescent plasma in critically ill patients with COVID-19: An early phase 1 descriptive study.多剂量恢复期血浆用于COVID-19危重症患者的经验：一项1期早期描述性研究。
Health Sci Rep. 2024 Mar 7;7(3):e1949. doi: 10.1002/hsr2.1949. eCollection 2024 Mar.
3
Perceptions of Saudis Toward Participating in the COVID-19 Convalescent Plasma Clinical Trial.沙特人对参与新冠康复者血浆临床试验的看法。
Cureus. 2023 Nov 16;15(11):e48879. doi: 10.7759/cureus.48879. eCollection 2023 Nov.
4
A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019.一项评估恢复期免疫球蛋白与恢复期血浆用于治疗 2019 年冠状病毒病住院患者的随机对照研究。
Clin Infect Dis. 2023 Oct 5;77(7):964-971. doi: 10.1093/cid/ciad305.
5
Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?是否有恢复使用血浆疗法或中和康复期抗体疗法来治疗新冠病毒变种，我们是否正在重新思考防范计划？
Transfus Apher Sci. 2023 Jun;62(3):103726. doi: 10.1016/j.transci.2023.103726. Epub 2023 May 8.
6
Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials.恢复期血浆疗法治疗 COVID-19 的随机对照试验的系统评价和荟萃分析。
Viruses. 2023 Mar 16;15(3):765. doi: 10.3390/v15030765.
7
The development of COVID-19 treatment.COVID-19 治疗的发展。
Front Immunol. 2023 Jan 26;14:1125246. doi: 10.3389/fimmu.2023.1125246. eCollection 2023.
8
Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications.中和抗体对 SARS-CoV-2 感染的保护作用和保护机制及其潜在的临床意义。
Front Immunol. 2023 Jan 19;14:1055457. doi: 10.3389/fimmu.2023.1055457. eCollection 2023.
9
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.用于COVID-19治疗的康复期血浆（高免疫球蛋白）：最新情况
Process Biochem. 2023 Apr;127:66-81. doi: 10.1016/j.procbio.2023.01.018. Epub 2023 Jan 31.
10
Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment.康复期或对照血浆输注治疗早期门诊 COVID-19 后，地方性人冠状病毒抗体水平保持不变。
mBio. 2023 Feb 28;14(1):e0328722. doi: 10.1128/mbio.03287-22. Epub 2023 Jan 10.

本文引用的文献

1
Early Outpatient Treatment for Covid-19 with Convalescent Plasma.Covid-19 的早期门诊康復期血浆治疗。
N Engl J Med. 2022 May 5;386(18):1700-1711. doi: 10.1056/NEJMoa2119657. Epub 2022 Mar 30.
2
Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use.使用索托维单抗后新冠病毒德尔塔变异株中的耐药突变
N Engl J Med. 2022 Apr 14;386(15):1477-1479. doi: 10.1056/NEJMc2120219. Epub 2022 Mar 9.
3
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.卡司瑞韦单抗和伊德韦单抗联合治疗住院 COVID-19 患者（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2022 Feb 12;399(10325):665-676. doi: 10.1016/S0140-6736(22)00163-5.
4
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.高滴度亚甲蓝处理的恢复期血浆作为 COVID-19 门诊患者的早期治疗：一项随机、安慰剂对照试验。
Lancet Respir Med. 2022 Mar;10(3):278-288. doi: 10.1016/S2213-2600(21)00545-2. Epub 2022 Feb 9.
5
The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials.中和单克隆抗体对 COVID-19 门诊患者结局的影响：一项随机对照试验的系统评价和荟萃分析。
J Med Virol. 2022 May;94(5):2222-2229. doi: 10.1002/jmv.27623. Epub 2022 Feb 7.
6
Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response.既往针对人类普通感冒冠状病毒的体液免疫会对 SARS-CoV-2 抗体的保护性应答产生负面影响。
Cell Host Microbe. 2022 Jan 12;30(1):83-96.e4. doi: 10.1016/j.chom.2021.12.005. Epub 2021 Dec 7.
7
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.恢复期血浆对 COVID-19 重症患者器官支持无依赖天数的影响：一项随机临床试验。
JAMA. 2021 Nov 2;326(17):1690-1702. doi: 10.1001/jama.2021.18178.
8
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.恢复期血浆或高免疫球蛋白用于 COVID-19 患者：一项实时系统评价。
Cochrane Database Syst Rev. 2021 May 20;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub4.
9
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.早期高滴度血浆疗法预防老年人重症 COVID-19。
N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.